Merck, Inc.

🇵🇭Philippines
Ownership
Subsidiary
Employees
-
Market Cap
$295.3B
Website
http://www.merck.ph
Clinical Trials
Related News

A Study to Evaluate the Safety and Efficacy of Raltegravir (MK0518) in HIV-Infected Patients Failing Current Antiretroviral Therapies (MK0518-018 EXT2)

Phase 3
Completed
Conditions
HIV Infections
Interventions
Drug: raltegravir potassium
First Posted Date
2006-02-17
Last Posted Date
2015-09-07
Lead Sponsor
Merck Sharp & Dohme LLC
Target Recruit Count
352
Registration Number
NCT00293267

Open, Pharmacokinetic Study of Caspofungin Acetate in Immunocompromised Young Children With Febrile Neutropenia (0991-042)

Phase 2
Completed
Conditions
Fungal Infection
Interventions
Drug: caspofungin acetate
First Posted Date
2006-02-15
Last Posted Date
2017-02-23
Lead Sponsor
Merck Sharp & Dohme LLC
Target Recruit Count
16
Registration Number
NCT00292071

A Phase IIA Study of MK0457 in Patients With Cancer of the Lung (0457-006)

Phase 2
Terminated
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
Drug: MK0457
First Posted Date
2006-02-13
Last Posted Date
2015-07-27
Lead Sponsor
Merck Sharp & Dohme LLC
Target Recruit Count
22
Registration Number
NCT00290550

MK0431 Monotherapy Study in Patients With Type 2 Diabetes Mellitus (0431-040)

Phase 3
Completed
Conditions
Type 2 Diabetes Mellitus
Interventions
Drug: sitagliptin phosphate
First Posted Date
2006-02-10
Last Posted Date
2015-06-15
Lead Sponsor
Merck Sharp & Dohme LLC
Target Recruit Count
530
Registration Number
NCT00289848

Lipid Efficacy and Safety in Participants With Mixed Hyperlipidemia (MK-0524B-024)

First Posted Date
2006-02-10
Last Posted Date
2018-08-31
Lead Sponsor
Merck Sharp & Dohme LLC
Target Recruit Count
2340
Registration Number
NCT00289900

Concomitant Use of Hepatitis A Vaccine, Inactivated With Haemophilus b Conjugate Vaccine (Meningococcal Protein Conjugate) and Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed Given to Healthy Children 15 Months of Age (V251-068)

Phase 4
Completed
Conditions
Hepatitis A Virus
First Posted Date
2006-02-10
Last Posted Date
2017-04-13
Lead Sponsor
Merck Sharp & Dohme LLC
Target Recruit Count
1274
Registration Number
NCT00289913

Safety, Tolerability and Maximum Tolerated Dose of Oral AP23573 in Combination With Doxorubicin (8669-015)

Phase 1
Completed
Conditions
Cancer
Sarcoma
Interventions
Drug: ridaforolimus
Drug: Doxorubicin
First Posted Date
2006-02-08
Last Posted Date
2015-07-22
Lead Sponsor
Merck Sharp & Dohme LLC
Target Recruit Count
37
Registration Number
NCT00288431

A Research Study to Evaluate the Safety and Effectiveness of MK0686 for the Treatment of Postherpetic Neuralgia (Also Known as PHN or Post Shingles Pain) (0686-005)

Phase 2
Terminated
Conditions
Neuralgia, Postherpetic
First Posted Date
2006-01-27
Last Posted Date
2015-11-23
Lead Sponsor
Merck Sharp & Dohme LLC
Target Recruit Count
12
Registration Number
NCT00282763

A Study to Evaluate the Effect of MK0966 (Rofecoxib) on the Recurrence of Colorectal Adenomas (0966-122)

Phase 3
Completed
Conditions
Colorectal Adenoma
First Posted Date
2006-01-26
Last Posted Date
2017-05-09
Lead Sponsor
Merck Sharp & Dohme LLC
Target Recruit Count
2586
Registration Number
NCT00282386

Safety and Efficacy of MK0736 & MK0916 in Patients With Hypertension (High Blood Pressure)(0736-003)(COMPLETED)

Phase 2
Completed
Conditions
Hypertension
Interventions
Drug: MK0736
Drug: MK0916
Drug: Placebo
First Posted Date
2006-01-11
Last Posted Date
2015-07-03
Lead Sponsor
Merck Sharp & Dohme LLC
Target Recruit Count
249
Registration Number
NCT00274716
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy